Peptides and Male Vitality: Research on Testosterone & Sexual Function

Explore clinical and preclinical studies on peptides like VDAC1-derived compounds, PT-141, and kisspeptin showing effects on testosterone synthesis, erectile function, and sexual arousal in male models and human trials. Click for details.

Peptides—short amino acid chains—offer targeted modulation of endocrine and neural pathways relevant to male reproductive health. While not a panacea, specific peptides demonstrate promising effects on testosterone production and sexual function in preclinical and early human research. Below, we review the evidence from peer-reviewed studies and clinical trials.

Peptides Targeting Testosterone Synthesis

VDAC1-Derived Peptides: Direct Testosterone Boost via Mitochondrial Pathways

Voltage-dependent anion channel 1 (VDAC1) peptides represent a novel class targeting steroidogenesis. In male rats, oral or subcutaneous administration of VDAC1-derived peptides (TVS167, TV159-172, N163-166) significantly elevated circulating testosterone levels without relying on luteinizing hormone (LH) stimulation. These peptides facilitate cholesterol transport to mitochondrial StAR protein, a rate-limiting step in testosterone biosynthesis.

Key Findings: Continuous 24-hour infusion increased plasma testosterone ~10-fold; 88-day oral treatment in chemically-castrated rats restored testosterone to normal levels while preserving testicular morphology. Effects were LH-independent, suggesting direct gonadal action.
Frontiers in Endocrinology, 2023: "Oral administration of VDAC1-derived small molecule peptides increases circulating testosterone levels in male rats"​
PMCID: PMC9846164 (full text)​

A related mitochondrial-targeting peptide, TVS167, elicited testosterone formation in isolated rat testes ex vivo and in vivo, bypassing hypothalamic-pituitary-gonadal axis disruptions. This positions VDAC1 peptides as potential alternatives to traditional testosterone replacement therapy (TRT) with fewer side effects.
PMCID: PMC4428411: "Peptide Targeting of Mitochondria Elicits Testosterone Formation"​

Human Translation: Preclinical only; Phase I/II trials needed for hypogonadism.

Peptides Enhancing Sexual Function and Libido

PT-141 (Bremelanotide): Central Melanocortin Activation for Erections

PT-141, a synthetic melanocortin receptor agonist (MC3R/MC4R), stimulates sexual arousal and erectile function via central nervous system pathways, independent of nitric oxide (NO) or vascular mechanisms. Human studies confirm rapid, dose-dependent erections in healthy men and erectile dysfunction (ED) patients.

Key Findings: Subcutaneous PT-141 (1.25–7.5 mg) induced erections in 80–100% of men within 30–60 minutes, lasting 2–6 hours. Effective in psychogenic and organic ED; minimal cardiovascular effects.
PubMed 2003: "PT-141: a melanocortin agonist for the treatment of sexual dysfunction"​

A 2025 review of intravenous peptides corroborates PT-141's CNS-mediated pro-erectile effects.
PMID: 40069591: "Intravenous peptides and amino acids for erectile dysfunction"​

Note: FDA-approved as Vyleesi for female HSDD; male applications ongoing.

Kisspeptin: Upstream Hypothalamic Regulation of Arousal

Kisspeptin, a neuropeptide, modulates GnRH neurons to influence testosterone and sexual behavior. Intravenous kisspeptin enhances sexual brain processing and penile tumescence in men with hypoactive sexual desire disorder (HSDD).

Key Findings: RCT (32 healthy men): Kisspeptin-54 (0.1–3 nmol/kg) increased posterior cingulate/subgenual cingulate activity (sexual arousal centers) by 56% vs. placebo; ↑ penile circumference and desire ratings. No acute testosterone change, but chronic potential via GnRH.
JAMA Network Open 2023: "Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men"​
PMCID: PMC9898824 (full text)​

Ongoing: SP16 SERPIN-like peptide trial for testosterone/libido in hypogonadal men.
ClinicalTrials.gov NCT03651089

​

Research Gaps and Considerations

Testosterone: Strong rat data (VDAC1); human trials limited to indirect boosters (e.g., kisspeptin ↑ GnRH → LH → T).

Sexual Function: PT-141/kisspeptin validated in RCTs; mechanism-specific (not "all peptides").

Safety: Favorable in trials; no broad androgenic risks. Always physician-supervised.

These studies highlight peptides' potential for precision male vitality support. Further RCTs needed for routine clinical use. 

Page Disclaimer:

 The information provided in this section is intended strictly for informational and research purposes only. Our articles discuss published studies, emerging scientific discussions, and general laboratory topics related to research compounds. Nothing in this section is intended to diagnose, treat, cure, or prevent any disease.